Addyi (flibanserin), the drug to increase female libido had a timid entry into the market with very few prescriptions considering the “hype.” Bloomberg Business reported 227 prescriptions in the first month. That’s a pittance considering Valeant paid $1 billion for the drug.
I am unlikely to help Valeant recoup their investment, because the more I read about this drug, the worse it looks. Here’s why:
It barely works
One of the study endpoints (meaning …